How Many Medical Providers Have Been Charged with Felonies for Opioid Fraud in 2018?

The number is 601, and the government has never stopped counting

Six hundred and one. That was the figure the Department of Justice announced on June 28, 2018, and it was the largest coordinated healthcare fraud enforcement action in the history of the federal government. The number included 165 licensed medical professionals. It spanned 58 federal districts. And the alleged fraud it represented exceeded two billion dollars in false billings submitted to Medicare, Medicaid, TRICARE, and private insurance carriers, a sum that the government did not present as an abstraction but as the aggregate cost of a prescribing apparatus it had decided to dismantle with prosecutorial force rather than regulatory adjustment.

Of the 601 individuals charged, 162 were charged for conduct connected to opioid prescribing and distribution. Among those 162, the government identified 76 physicians, 23 pharmacists, and 19 nurses. The conduct attributed to them accounted for approximately 13 million illegal dosages of opioid medications. One should pause over that figure. Thirteen million dosages is not a rounding error in a prescription monitoring database. It is a quantity the government characterized as the output of a system in which clinical judgment had been replaced by financial incentive, and in which the prescription pad had become, in the Department’s language, an instrument of distribution rather than treatment.

The 2018 Takedown was not the beginning of federal opioid enforcement against medical providers. But it established the scale at which the government intended to operate, and that scale has not contracted in the eight years since.

The anatomy of the charges was federal and it was severe

The felony charges brought against medical providers in the 2018 Takedown were not uniform, though they shared a common architecture. The predominant charge was unlawful distribution of controlled substances under 21 U.S.C. 841(a)(1), a statute that draws no formal distinction between a physician who prescribes outside the usual course of professional practice and a distributor who operates without a medical license at all. The penalty for a Schedule II violation under that statute is imprisonment of not more than twenty years. Where death or serious bodily injury results from the substance distributed, the mandatory minimum is twenty years and the statutory ceiling becomes life imprisonment.

Conspiracy to distribute controlled substances under 21 U.S.C. 846 appeared in the majority of multi-defendant indictments, because the government’s theory in most 2018 cases was organizational rather than individual: clinic operators, prescribers, pharmacists, patient recruiters, and billing coordinators functioning as components of a single scheme. Healthcare fraud under 18 U.S.C. 1347 carried a maximum of ten years, or twenty years where the violation resulted in serious bodily injury. Money laundering charges under 18 U.S.C. 1956 carried a maximum of twenty years per count. And in cases where the Anti-Kickback Statute was implicated, the government added conspiracy to pay or receive healthcare kickbacks, a felony carrying five years per count and, more consequentially, mandatory exclusion from all federal healthcare programs upon conviction.

The physician who believes an opioid fraud charge is a single count on a single theory has not read the indictments the government produced in 2018. The indictments were layered. The penalties were cumulative. The sentencing exposure in a multi-count case could reach the functional equivalent of a life sentence for a provider in middle age.

The geographic pattern revealed a theory of prosecution

Thirty state Medicaid Fraud Control Units participated in the 2018 enforcement action, and the geographic distribution of the charges was not proportional to population. The government concentrated its prosecutorial resources in regions where prescribing volume, overdose mortality, and ARCOS data converged to produce statistical profiles the Department regarded as actionable. Louisiana produced 26 defendants from the Baton Rouge area alone. The Southern District of Alabama generated nine arrests for unlawful distribution of morphine, hydrocodone, oxycodone, oxymorphone, OxyContin, and fentanyl, with defendants drawn from Selma and Mobile. The Middle District of Florida charged 19 defendants. The Northern District of Illinois charged multiple physicians in the Chicago metropolitan area. The District of Nevada filed prescription opioid charges against four individuals in connection with $3.7 million in alleged losses.

But the geographic concentration that mattered most in 2018 was not announced in June. It was announced in October, when the Department of Justice created the Appalachian Regional Prescription Opioid Strike Force, a permanent prosecutorial unit spanning ten federal districts across West Virginia, Kentucky, Ohio, Tennessee, Alabama, and Virginia. Within four months of its formation, ARPO charged 60 defendants, 53 of them licensed medical professionals, in connection with more than 350,000 prescriptions and 32 million pills. The creation of ARPO was not a response to the 2018 Takedown. It was its extension into institutional permanence, and the government has never dissolved it.

The second ARPO action, announced in September 2019, charged 13 additional individuals, 11 of them physicians. The specificity of that ratio tells you something about what the apparatus was designed to produce.

The sentences that followed were not theoretical

The 2018 charging figures acquire their operational weight only when one examines what happened to the providers who were convicted. In Houston, Gazelle Craig and Shane Faithful, a physician and a pain clinic operator, received 35 years each after a jury found they had conspired to distribute controlled substances through a clinic that processed over 60 patients per day at approximately $300 per prescription, cash only, generating daily proceeds that exceeded $15,000. In Montgomery County, Pennsylvania, a physician who prescribed oxycodone, hydrocodone, and fentanyl to patients he knew would abuse the medications received more than 12 years for drug distribution, healthcare fraud, and money laundering. In a prosecution that linked Michigan and Ohio, 16 defendants, 12 of them physicians, were sentenced for distributing 6.6 million opioid pills and submitting $250 million in false billings over an eleven-year period.

These were not sentences calculated to correct prescribing behavior. They were sentences calculated to remove providers from the profession and from the population for periods measured in decades rather than months, and the government’s sentencing memoranda in each case employed the 2018 Takedown statistics as contextual evidence that the conduct was not isolated but symptomatic of a systemic failure the Department had committed itself to prosecuting at volume. A physician in Philadelphia who operated a practice under the name A+ Pain Management received 20 years. The name of the practice appeared in the sentencing transcript. One imagines the judge paused over it.

The enforcement trajectory since 2018 has been one of expansion

The 2018 figure of 601 defendants was, at the time, the largest in the history of coordinated federal healthcare fraud enforcement. The government has since treated that figure not as a ceiling but as a benchmark against which subsequent operations are measured. In 2020, 345 defendants were charged in connection with more than six billion dollars in alleged fraud, tripling the dollar amount of the 2018 action. In 2023, the number of defendants declined to 78, but the alleged fraud exceeded $2.5 billion, indicating a shift toward higher-value cases involving fewer but more consequential targets. In 2024, 193 defendants were charged with more than $2.5 billion in alleged fraud. And in June 2025, the Department announced 324 defendants charged across 50 federal districts in connection with $14.6 billion in intended losses, more than doubling the previous dollar record set in 2020 and involving 96 licensed medical professionals, 74 of whom were charged in 58 cases for the alleged diversion of more than 15 million pills of prescription opioids.

The year-over-year fluctuation in the number of defendants is less instructive than the consistency of the enforcement apparatus itself. The annual National Health Care Fraud Takedown has continued without interruption through two presidential administrations, three Attorneys General, and a pandemic that suspended most federal operations but not the Medicare Fraud Strike Force. The ARPO Strike Force remains operational across its original ten districts. The Health Care Fraud Unit within the Criminal Division’s Fraud Section has increased its data analytics capacity in each successive year. The government has not paused.

What has changed is not the government’s appetite for prosecution but the sophistication of the instruments it employs to identify targets. In 2025, the Department announced the creation of the Health Care Fraud Data Fusion Center, a multi-agency analytical operation that combines cloud computing, artificial intelligence, and advanced data analytics to detect anomalous prescribing and billing patterns before they mature into the figures that populate indictments. The head of the Criminal Division described the Fusion Center as the beginning of a new era of data-driven prevention and aggressive prosecution. For a practitioner whose controlled substance prescribing generates a detectable statistical pattern, the interval between the emergence of the pattern and the government’s awareness of it has contracted to something that resembles proximity.

The 2018 figures acquire a different meaning in 2026

A physician or pharmacist reading these figures in March 2026 might regard the 2018 Takedown as a historical event, a particular exercise of prosecutorial discretion by a particular administration that has since been replaced and replaced again. That reading would be incorrect. The 2018 action established three precedents that have governed every subsequent enforcement year and that now operate as structural features of the federal approach to opioid prescribing by medical professionals.

The first precedent was scale. Before 2018, the coordinated takedown was measured in dozens of defendants. The 601-defendant operation demonstrated that the government possessed the logistical capacity to investigate, charge, and process hundreds of providers across the majority of federal judicial districts, and the 2020 and 2025 operations confirmed that this capacity was not a one-time allocation but a permanent feature of the enforcement apparatus.

The second precedent was the integration of opioid distribution charges with healthcare fraud charges in the same indictment. The 162 opioid defendants in 2018 were not charged in isolation from the broader fraud apparatus. They were charged within it, which meant that the evidentiary record assembled for fraud purposes, the billing data, the patient rosters, the financial flows, became available to support the controlled substance charges, and the reverse was also true. This integration has persisted. The 2025 Takedown charged opioid diversion and healthcare fraud in the same coordinated action, drawing on the same multi-agency investigative infrastructure, and the Data Fusion Center was designed to make that integration automatic rather than deliberate.

The third precedent was the creation of permanent regional prosecutorial infrastructure. The ARPO Strike Force was not a task force assembled for a single operation and dissolved upon its completion. It was a standing prosecutorial body with embedded attorneys, co-located investigators, and a geographic mandate that has not been withdrawn. The government built an institution in 2018. That institution operates today.

DEFENSE TEAM SPOTLIGHT

Todd Spodek

Lead Attorney & Founder

Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.

NY Bar Admitted Multi-State Licensed Federal Courts

Meet the Full Team

What Ruan altered and what it did not

The Supreme Court’s 2022 decision in Ruan v. United States modified the legal standard for prosecuting physicians under 21 U.S.C. 841 by requiring the government to prove that the defendant subjectively knew or intended that the prescribing conduct was unauthorized, rather than proving only that the conduct was objectively unreasonable by the standards of medical practice. The decision produced reversals, retrials, and a period of recalibration within the Department of Justice. It did not produce a reduction in the number of providers charged.

The 2024 and 2025 Takedown figures demonstrate that the government has absorbed the Ruan standard and adapted its prosecutorial methodology to satisfy it. The indictments filed after Ruan are more granular in their allegations of subjective knowledge. They incorporate evidence of warnings received, compliance deficiencies identified and not corrected, financial arrangements that the government argues reveal awareness of illegitimacy. The Data Fusion Center’s analytical capacity is designed, in part, to produce precisely this kind of evidence: prescribing patterns so far outside the norm that the inference of subjective knowledge becomes, in the government’s view, inescapable. Ruan raised the evidentiary bar. The government responded by building a taller ladder.

For the practitioner who prescribed controlled substances in 2018 and continues to do so in 2026, the relevant calculation is not whether enforcement has relaxed since the 2018 Takedown. It has not. The relevant calculation is whether the documentation practices, clinical rationale, and compliance protocols that govern current prescribing activity could withstand scrutiny by an apparatus that is more analytically capable, more institutionally coordinated, and more experienced in prosecuting medical professionals than the apparatus that charged 601 defendants eight years ago. The analytical systems review prescribing data without fatigue and without the passage of statutes of limitation that constrain human memory. A prescription written in 2019 that generated an anomaly in the PDMP may not have triggered an investigation in 2020. Whether it triggers one in 2026 depends on the Data Fusion Center’s retrospective analytical capacity, and that capacity is, by the government’s own description, designed to identify patterns across time.

The figure endures because the apparatus endures

Six hundred and one defendants charged in a single coordinated federal action. One hundred and sixty-two of them charged for opioid prescribing and distribution. Seventy-six of those, physicians. Twenty-three, pharmacists. Nineteen, nurses. Thirteen million dosages attributed to their conduct. Two billion dollars in alleged fraud. These numbers were published by the Department of Justice on a Thursday afternoon in June 2018, and they were read by physicians in examination rooms and pharmacists behind dispensing counters and nurse practitioners in rural clinics where the nearest pain specialist was ninety minutes away, and each of those professionals understood, with a specificity that no press release could convey, that the government had decided to prosecute medical providers for opioid conduct at a scale that had been reserved for narcotics trafficking organizations.

The enforcement architecture constructed around the 2018 Takedown has not been dismantled. It has been refined, expanded, equipped with artificial intelligence, and replicated in jurisdictions that were not among the original 58 federal districts. The ARPO Strike Force operates. The Medicare Fraud Strike Force operates. The Data Fusion Center operates. The annual takedown continues. The trajectory from 2018 to 2026 is not a line that crests and descends. It is an incline.

If you are a physician, pharmacist, or healthcare provider whose prescribing practices have generated questions you cannot answer with documentation, or if you have received contact from a federal agency whose purpose you do not yet understand, a consultation with counsel experienced in DEA enforcement and federal controlled substances prosecution is the act that determines whether the government’s next annual figure includes your name. The consultation should occur before the question becomes an investigation. It should occur before the investigation becomes an indictment. It should occur now.